Biotech Values

[DewDiligence]

ENTA—Mavyret scripts plateaued in the week ending 2/16/18, showing 0.2% growth in NRx and 0.9% growth in TRx (according to IMS).

ABBV’s patient share for the week was 37.7% for NRx and 33.5% for TRx, both down slightly from the prior week (#msg-138602647).

Do these data mean that Mavyret's growth trajectory in the US market has materially changed? It's too soon to say, but I strongly doubt that.